[1] Sipe JD,Benson MD,Buxbaum JN,et al. Nomenclature 2014: Amyloid fibril proteins and clinical classification of the amyloidosis[J]. Amyloid,2014,21(4): 221-224.[2] Palladini G,Milani P,Merlini G. Novel strategies for the diagnosis and treatment of cardiac amyloidosis[J]. Expert Rev Cardiovasc Ther,2015,13(11):1195-1211.
[3] Dispenzieri A,Gertz MA,Kyle RA,et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis[J]. J Clin Oncol,2004,22(18):3751-3757.?
[4] Wechalekar AD,Schonland SO,Kastritis E,et al. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis[J]. Blood,2013,121(17):3420-3427.
[5] Aus dSF,Hein S,Prestel S,et al. Carpal tunnel syndrome and spinal canal stenosis: harbingers of transthyretin amyloid cardiomyopathy?[J]. Clin Res Cardiol,2019,Apr5.DOI:10.1007/s00392-019-01467-1 LEpub ahead of print J?
[6] de Larrea C F,Verga L,Morbini P,et al. A practical approach to the diagnosis of systemic amyloidoses[J]. Blood, 2015,125(14):2239-2244.
[7] Dogan A. Amyloidosis: insights from proteomics[J]. Annu Rev Pathol,2017,12:277-304.?
[8] Sperry BW,Vranian MN,Hachamovitch R,et al. Are classic predictors of voltage valid in cardiac amyloidosis? A contemporary analysis of electrocardiographic findings[J]. Int J Cardiol,2016,214:477-481.?
[9] Rapezzi C,Merlini G,Quarta CC,et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types[J]. Circulation,2009,120(13):1203-1212.?
[10] Pagourelias ED,Mirea O,Vovas G,et al. Relation of regional myocardial structure and function in hypertrophic cardiomyopathy and amyloidois:a combined two-dimensional speckle tracking and cardiovascular magnetic resonance analysis[J]. Eur Heart J Cardiovasc Imaging,2019,20(4):426-437.?
[11] Pradel S,Magne J,Jaccard A,et al. Left ventricular assessment in patients with systemic light chain amyloidosis: a 3-dimensional speckle tracking transthoracic echocardiographic study[J]. Int J Cardiovasc Imaging, 2019,35(5):845-854.?
[12] Binder C,Duca F,Stelzer PD,et al. Mechanisms of heart failure in transthyretin vs. light chain amyloidosis[J]. Eur Heart J Cardiovasc Imaging,2019,20(5):512-524?
[13] Syed IS,Glockner JF,Feng D,et al. Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis[J]. JACC Cardiovasc Imaging,2010,3(2):155-164.?
[14] Banypersad SM,Fontana M,Maestrini V,et al. T1 mapping and survival in systemic light-chain amyloidosis[J]. Eur Heart J,2015,36(4):244-251.?
[15] Martinez-Naharro A,Kotecha T,Norrington K,et al. Native T1 and extracellular volume in?transthyretin amyloidosis[J]. JACC Cardiovasc Imaging,2018.?
[16] Pandey T,Alapati S,Wadhwa V,et al. Evaluation of myocardial strain in patients with Amyloidosis using Cardiac magnetic resonance feature Tracking[J]. Curr Probl Diagn Radiol,2017,46(4):288-294.?
[17] Gillmore JD,Maurer MS,Falk RH,et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis[J]. circulation,2016,133(24):2404-2412.?
[18] Coutinho MC,Cortez-Dias N,Cantinho G,et al. Reduced myocardial 123-iodine metaiodobenzylguanidine uptake: a prognostic marker in familial amyloid polyneuropathy[J]. Circ Cardiovasc Imaging,2013,6(5):627-636.?
[19] Lin G,Dispenzieri A,Kyle R,et al. Implantable cardioverter defibrillators in patients with cardiac amyloidosis[J]. J Cardiovasc Electrophysiol,2013,24(7):793-798.?
[20] Caccialanza R,Palladini G,Cereda E,et al. Nutritional counseling improves quality of life and preserves body weight in systemic immunoglobulin light-chain (AL) amyloidosis[J]. Nutrition,2015,31(10):1228-1234.?
[21] Palladini G,Dispenzieri A,Gertz MA,et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes[J]. J Clin Oncol,2012,30(36):4541-4549.?
[22] Palladini G,Milani P,Foli A,et al. Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach[J]. Haematologica,2014,99(4):743-750.?
[23] Palladini G,Milani P,Foli A,et al. Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients[J]. Leukemia,2014,28(12):2311-2316.
[24] Palladini G,Sachchithanantham S,Milani P,et al. A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis[J]. Blood, 2015,126(5):612-615.?
[25] Arnall JR,Usmani SZ,Adamu H,et al. Daratumumab, pomalidomide, and dexamethasone as a bridging therapy to autologous stem cell transplantation in a case of systemic light-chain amyloidosis with advanced cardiac involvement[J]. J Oncol Pharm Pract,2019,25(4):1021-1025.?
[26] Sanchorawala V,Palladini G,Kukreti V,et al. A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis[J]. Blood,2017,130(5):597-605.?
[27] Laina A,Gatsiou A,Georgiopoulos G,et al. RNA therapeutics in cardiovascular precision medicine[J]. Front Physiol,2018,9:953.?
[28] Wechalekar AD,Whelan C. Encouraging impact of doxycycline on early mortality in cardiac light chain (AL) amyloidosis[J]. Blood Cancer J,2017,7(3):e546.?
[29] Meshitsuka S,Shingaki S,Hotta M,et al. Phase 2 trial of daily, oral epigallocatechin gallate in patients with light-chain amyloidosis[J]. Int J Hematol,2017,105(3):295-308.?
[30] Gertz MA,Landau H,Comenzo RL,et al. First-in-human phase I/II study of NEOD001 in patients with light chain amyloidosis and persistent organ dysfunction[J]. J Clin Oncol,2016,34(10):1097-1103.?
[31] Benson MD,Waddington-Cruz M,Berk JL,et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis[J]. N Engl J Med,2018,379(1):22-31.?
[32] Maurer MS,Schwartz JH,Gundapaneni B,et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy[J]. N Engl J Med,2018,379(11):1007-1016.?
[33] Hawkins PN,Ando Y,Dispenzeri A,et al. Evolving landscape in the management of transthyretin amyloidosis[J]. Ann Med, 2015,47(8):625-638.?
[34] Cappelli F,Martone R,Taborchi G,et al. Epigallocatechin-3-gallate tolerability and impact on survival in a cohort of patients with transthyretin-related cardiac amyloidosis. A single-center retrospective study[J]. Intern Emerg Med,2018,13(6):873-880.?
[35] Kamal ZF,Bhat R. Resveratrol interferes with an early step in the fibrillization pathway of human lysozyme and modulates it towards Less-toxic, off-pathway aggregates[J]. Chembiochem,2018,19(2):159-170.?
[36] Palladini G,Merlini G. What is new in diagnosis and management of light chain amyloidosis?[J]. Blood, 2016,128(2):159-168.
[37] Hwa YL,Kumar SK,Gertz MA,et al. Induction therapy pre-autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluation[J]. Am J Hematol,2016,91(10):984-988.?
[38] Algalarrondo V,Antonini T,Théaudin M,et al. Cause of death analysis and temporal trends in survival after liver transplantation for transthyretin familial amyloid polyneuropathy[J]. Amyloid,2018,25(4):253-260.?
[39] Careddu L,Zanfi C,Pantaleo A,et al. Combined heart-liver transplantation:a single-center experience[J]. Transpl Int, 2015,28(7):828-834.